ORIC PHARMACEUTICALS, INC. (ORIC) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.02M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-290.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $786.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $615.00K.
ORIC PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $11.00K | $1.15B | $-1.02M | $-769.50M | $381.26M | 3 month · $7.09M | (m) |
| 2026-03-31 | $0.00 | $11.00K | $1.14B | $-290.00K | $-728.01M | $415.56M | 3 month · $6.90M | (m) |
| 2025-12-31 | $0.00 | $11.00K | $1.08B | $786.00K | $-692.24M | $384.36M | 12 month · $25.04M | (m) |
| 2025-09-30 | $0.00 | $11.00K | $1.07B | $615.00K | $-661.74M | $406.92M | 3 month · $5.63M | (m) |
| 2025-06-30 | $0.00 | $9.00K | $952.95M | $187.00K | $-629.15M | $324.00M | 3 month · $6.57M | (m) |
| 2025-03-31 | $0.00 | $7.00K | $812.32M | $209.00K | $-592.79M | $219.74M | 3 month · $6.55M | (m) |
| 2024-12-31 | $0.00 | $7.00K | $805.51M | $379.00K | $-562.77M | $243.12M | 12 month · $20.21M | (m) |
| 2024-09-30 | $0.00 | $7.00K | $799.73M | $722.00K | $-526.47M | $273.99M | 3 month · $5.06M | (m) |
| 2024-06-30 | $0.00 | $7.00K | $794.55M | $-256.00K | $-491.90M | $302.40M | 3 month · $5.00M | (m) |
| 2024-03-31 | $0.00 | $7.00K | $788.74M | $-162.00K | $-459.94M | $328.64M | 3 month · $4.96M | (m) |
| 2023-12-31 | $0.00 | $6.00K | $658.75M | $258.00K | $-434.93M | $224.09M | 12 month · $15.23M | (m) |
| 2023-09-30 | $0.00 | $6.00K | $654.37M | $-369.00K | $-406.60M | $247.41M | 3 month · $3.86M | (m) |
| 2023-06-30 | $0.00 | $6.00K | $650.48M | $-567.00K | $-381.12M | $268.80M | 3 month · $3.83M | (m) |
| 2023-03-31 | $0.00 | $5.00K | $561.48M | $-499.00K | $-358.18M | $202.81M | 3 month · $3.61M | (m) |
| 2022-12-31 | $0.00 | $5.00K | $557.87M | $-1.29M | $-334.23M | $222.35M | 12 month · $14.46M | 12 month · $399.00K |
| 2022-09-30 | (m) | $4.00K | $529.95M | $-1.75M | $-313.38M | $214.82M | 3 month · $3.29M | (m) |
| 2022-06-30 | (m) | $4.00K | $526.65M | $-1.23M | $-288.55M | $236.87M | 3 month · $4.09M | (m) |
| 2022-03-31 | (m) | $4.00K | $522.14M | $-802.00K | $-268.27M | $253.08M | 3 month · $3.94M | (m) |
| 2021-12-31 | $0.00 | $4.00K | $518.18M | $-103.00K | $-245.11M | $272.98M | 12 month · $12.85M | 12 month · $1.85M |
| 2021-09-30 | (m) | $4.00K | $513.87M | $-2.00K | $-222.34M | $291.54M | 3 month · $3.40M | 3 month · $1.85M |
| 2021-06-30 | (m) | $4.00K | $462.23M | $3.00K | $-203.91M | $258.32M | 3 month · $3.21M | (m) |
| 2021-03-31 | (m) | $4.00K | $458.96M | $17.00K | $-182.90M | $276.07M | 3 month · $2.74M | (m) |
| 2020-12-31 | $0.00 | $4.00K | $456.20M | $-31.00K | $-166.39M | $289.78M | 12 month · $5.28M | (m) |
| 2020-09-30 | (m) | $3.00K | $322.54M | $-29.00K | $-138.13M | $184.38M | 3 month · $1.68M | (m) |
| 2020-06-30 | (m) | $3.00K | $307.83M | (m) | $-112.59M | $195.25M | 3 month · $1.38M | (m) |
| 2020-03-31 | (m) | (m) | $3.15M | (m) | $-101.56M | $-98.42M | 3 month · $527.00K | (m) |
| 2019-12-31 | (m) | (m) | $2.61M | (m) | $-92.69M | $-90.08M | 12 month · $1.09M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-82.21M | 3 month · $271.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-75.94M | 3 month · $190.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-70.23M | 3 month · $191.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-64.43M | 12 month · $469.00K | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-43.61M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |